Authors: Aarons, L Karlsson, MO Mentre, F Rombout, F Steimer, JL van Peer, A

Citation: L. Aarons et al., Role of modelling and simulation in Phase I drug development, EUR J PH SC, 13(2), 2001, pp. 115-122

Authors: Gieschke, R Steimer, JL

Citation: R. Gieschke et Jl. Steimer, Pharmacometrics: modelling and simulation tools to improve decision makingin clinical drug development, EUR J DRUG, 25(1), 2000, pp. 49-58

Authors: Sheiner, LB Steimer, JL

Citation: Lb. Sheiner et Jl. Steimer, Pharmacokinetic/pharmacodynamic modeling in drug development, ANN R PHARM, 40, 2000, pp. 67-95

Authors: Jorga, K Fotteler, B Banken, L Snell, P Steimer, JL

Citation: K. Jorga et al., Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies, BR J CL PH, 49(1), 2000, pp. 39-48

Authors: Jorga, K Banken, L Fotteler, B Snell, P Steimer, JL

Citation: K. Jorga et al., Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone, CLIN PHARM, 67(6), 2000, pp. 610-620

Authors: Gieschke, R Fotteler, B Buss, N Steimer, JL

Citation: R. Gieschke et al., Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients, CLIN PHARMA, 37(1), 1999, pp. 75-86